Search research articles
Contact Us
Filters
Showing results (31-40 of 115) with videos related to
Page
of 12
Sort By:
Prostate Cancer and Prostatic Diseases
|
May 19, 2021
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
Daniel E Lage, M Dror Michaelson, Richard J Lee, et al.
Immunotherapy
|
January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma
Apoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Cancer Chemotherapy and Pharmacology
|
November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
Ana M Molina, Thomas E Hutson, James Larkin, et al.
Cancer
|
December 20, 2002
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors
M Dror Michaelson, David P Ryan, Charles S Fuchs, et al.
JCO Oncology Practice
|
February 2, 2021
Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic
Robert M Stern, M Dror Michaelson, Erica L Mayer, et al.
Urologic Oncology
|
January 9, 2014
Prognostic significance of indeterminate lung nodules in renal cell carcinoma
Rena Xu, Nora Horick, Francis J McGovern, et al.
Journal of Translational Medicine
|
July 4, 2007
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E Deprimo, Carlo L Bello, John Smeraglia, et al.
Journal of Oncology Practice
|
September 22, 2010
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa
David Cella, Joseph C Cappelleri, Andrew Bushmakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M Dror Michaelson, Donald S Kaufman, Hang Lee, et al.
Cancer
|
August 23, 2008
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Ronald M Bukowski, Robert A Figlin, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 115) with videos related to
Sort By:
Page
of 12
Prostate Cancer and Prostatic Diseases
|
May 19, 2021
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
Daniel E Lage, M Dror Michaelson, Richard J Lee, et al.
Immunotherapy
|
January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma
Apoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Cancer Chemotherapy and Pharmacology
|
November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
Ana M Molina, Thomas E Hutson, James Larkin, et al.
Cancer
|
December 20, 2002
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors
M Dror Michaelson, David P Ryan, Charles S Fuchs, et al.
JCO Oncology Practice
|
February 2, 2021
Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic
Robert M Stern, M Dror Michaelson, Erica L Mayer, et al.
Urologic Oncology
|
January 9, 2014
Prognostic significance of indeterminate lung nodules in renal cell carcinoma
Rena Xu, Nora Horick, Francis J McGovern, et al.
Journal of Translational Medicine
|
July 4, 2007
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E Deprimo, Carlo L Bello, John Smeraglia, et al.
Journal of Oncology Practice
|
September 22, 2010
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa
David Cella, Joseph C Cappelleri, Andrew Bushmakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M Dror Michaelson, Donald S Kaufman, Hang Lee, et al.
Cancer
|
August 23, 2008
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Ronald M Bukowski, Robert A Figlin, et al.
Page
of 12